Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of the study is to evaluate in diabetic patients affected by diabetic retinopathy epivascular glia regression and macular pigment restoration after faricimab injection in diabetic retinopathy in a 1 year follow up
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Diabetic macular edema treated with Eylea 2 mg | Diabetic macular edema treated with Eylea 2 mg |
| |
| Diabetic macular edema treated with Faricimab |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Faricimab Injection [Vabysmo] | Drug | One group treated with faricimab and the other one treated with Aflibercept |
|
| Measure | Description | Time Frame |
|---|---|---|
| Epivascular glia regression | Epivascular glia regression | From January 2025 to January 2026 |
| Macular pigment changes | Macular pigment changes | From January 2025 to January 2026 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
The study population includes adult patients,, diagnosed with diabetic macular edema in diabetic retinopathy, treated with eylea 2 or faricimab
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Naples, Federico II, Napoli, Napoli | Naples | Napoli | 80127 | Italy |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003930 | Diabetic Retinopathy |
| ID | Term |
|---|---|
| D012164 | Retinal Diseases |
| D005128 | Eye Diseases |
| D003925 | Diabetic Angiopathies |
| D014652 | Vascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000723200 | faricimab |
| C533178 | aflibercept |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Aflibercept (2.0 mg) | Drug | Aflibercept 2 mg intravitreal injection |
|
| D002318 |
| Cardiovascular Diseases |
| D048909 | Diabetes Complications |
| D003920 | Diabetes Mellitus |
| D004700 | Endocrine System Diseases |